23948-77-8

Usage

Uses

Used in Pharmaceutical Industry:
BIPHENYLACETICACID is used as a key intermediate in the synthesis of various drugs due to its biological activities. Its derivatives are significant in the pharmaceutical industry, particularly for the production of drugs with anti-inflammatory, analgesic, and antipyretic properties.
Used in Chemical Synthesis:
BIPHENYLACETICACID is used as a building block in the synthesis of a wide range of chemical compounds. Its versatile structure allows for the creation of various derivatives, making it a valuable component in the development of new chemical entities.

InChI:InChI=1/C14H12O2/c15-14(16)10-11-5-4-8-13(9-11)12-6-2-1-3-7-12/h1-9H,10H2,(H,15,16)

Upstream product

• 3112-01-4 3-phenylacetophenone 
• 51780-76-8 2-([1,1'-biphenyl]-3-yl)acetonitrile 
• 71912-71-5 3-(2-hydroxy-1-ethyl)-1,1'-biphenyl 
• 75852-28-7 2-biphenyl-3yl-acetic acid methyl ester 
• 75852-25-4 methyl 5-amino-3-biphenylylacetate hydrochloride 
• 220099-04-7 Biphenyl-3-yl-acetic acid benzyl ester 
• 14704-31-5 3-(bromomethyl)-1,1'-biphenyl 
• 1878-67-7 3-Bromophenylacetic acid 
• 220099-03-6 benzyl (3-bromophenyl)-acetate 
• 2113-57-7 3-bromobiphenyl 
• 75852-22-1 methyl 5-acetamido-3-biphenylylacetate 
• 643-93-6 3-methylbiphenyl 
• 98-80-6 phenylboronic acid 
• 71912-70-4 ethyl 2-((1,1'-biphenyl)-3-yl)acetate 

Downstream Products

• 897015-56-4 KX₁-307 
• 1002100-58-4 OMDM₁₂₉ 
• 1417519-94-8 C₂₅H₂₂N₂O₂ 
• 1618094-54-4 C₂₈H₂₆N₂O₃ 
• 1618094-75-9 C₂₄H₁₈N₂O₃ 
• 1618095-10-5 N-hydroxy-3-(4-(5-([1,1'-biphenyl]-3-ylmethyl)-1,3,4-oxadiazol-2-yl)phenyl)acrylamide 
• 1618094-32-8 C₂₁H₁₅IN₂O 
• 729611-32-9 (13E)-9,15-dioxo-16-(3-phenylphenyl)-17,18,19,20-tetranol-5-thia-8-aza-10-oxaprost-13-enoic acid-n-butylester 
• 729611-34-1 4-[(2-{(4S)-4-[(1E,3S)-4-(1,1'-biphenyl-3-yl)-3-hydroxybut-1-enyl]-2-oxo-1,3-oxazolidin-3-yl}ethyl)sulfanyl]butanoic acid 
• 51498-07-8 2-(3-biphenylyl)propanoic acid 

Relevant academic research and scientific papers

Visible-Light-Enabled Carboxylation of Benzyl Alcohol Derivatives with CO2 Using a Palladium/Iridium Dual Catalyst

A highly efficient carboxylation of benzyl alcohol derivatives with CO2 using a palladium/iridium dual catalyst under visible-light irradiation was developed. A wide range of benzyl alcohol derivatives could be employed to provide benzylic carboxylic acids in moderate to high yields. Mechanistic studies indicated that the oxidative addition of benzyl alcohol derivatives was possibly the rate-determining-step. It was also found that a switchable site-selective carboxylation between benzylic C?O and aryl C?Cl moieties could be achieved simply by changing the palladium catalyst.

Suppressing carboxylate nucleophilicity with inorganic salts enables selective electrocarboxylation without sacrificial anodes

Although electrocarboxylation reactions use CO2as a renewable synthon and can incorporate renewable electricity as a driving force, the overall sustainability and practicality of this process is limited by the use of sacrificial anodes such as magnesium and aluminum. Replacing these anodes for the carboxylation of organic halides is not trivial because the cations produced from their oxidation inhibit a variety of undesired nucleophilic reactions that form esters, carbonates, and alcohols. Herein, a strategy to maintain selectivity without a sacrificial anode is developed by adding a salt with an inorganic cation that blocks nucleophilic reactions. Using anhydrous MgBr2as a low-cost, soluble source of Mg2+cations, carboxylation of a variety of aliphatic, benzylic, and aromatic halides was achieved with moderate to good (34-78%) yields without a sacrificial anode. Moreover, the yields from the sacrificial-anode-free process were often comparable or better than those from a traditional sacrificial-anode process. Examining a wide variety of substrates shows a correlation between known nucleophilic susceptibilities of carbon-halide bonds and selectivity loss in the absence of a Mg2+source. The carboxylate anion product was also discovered to mitigate cathodic passivation by insoluble carbonates produced as byproducts from concomitant CO2reduction to CO, although this protection can eventually become insufficient when sacrificial anodes are used. These results are a key step toward sustainable and practical carboxylation by providing an electrolyte design guideline to obviate the need for sacrificial anodes.

Visible-Light-Driven External-Reductant-Free Cross-Electrophile Couplings of Tetraalkyl Ammonium Salts

Cross-electrophile couplings between two electrophiles are powerful and economic methods to generate C-C bonds in the presence of stoichiometric external reductants. Herein, we report a novel strategy to realize the first external-reductant-free cross-electrophile coupling via visible-light photoredox catalysis. A variety of tetraalkyl ammonium salts, bearing primary, secondary, and tertiary C-N bonds, undergo selective couplings with aldehydes/ketone and CO2. Notably, the in situ generated byproduct, trimethylamine, is efficiently utilized as the electron donor. Moreover, this protocol exhibits mild reaction conditions, low catalyst loading, broad substrate scope, good functional group tolerance, and facile scalability. Mechanistic studies indicate that benzyl radicals and anions might be generated as the key intermediates via photocatalysis, providing a new direction for cross-electrophile couplings.

A General, Activator-Free Palladium-Catalyzed Synthesis of Arylacetic and Benzoic Acids from Formic Acid

A new catalyst for the carboxylative synthesis of arylacetic and benzoic acids using formic acid (HCOOH) as the CO surrogate was developed. In an improvement over previous work, CO is generated in situ without the need for any additional activators. Key to success was the use of a specific system consisting of palladium acetate and 1,2-bis((tert-butyl(2-pyridinyl)phosphinyl)methyl)benzene. The generality of this method is demonstrated by the synthesis of more than 30 carboxylic acids, including non-steroidal anti-inflammatory drugs (NSAIDs), under mild conditions in good yields.

Nickel-Catalyzed Carboxylation of Benzylic C-N Bonds with CO2

A user-friendly Ni-catalyzed reductive carboxylation of benzylic C-N bonds with CO2 is described. This procedure outperforms state-of-the-art techniques for the carboxylation of benzyl electrophiles by avoiding commonly observed parasitic pathways, such as homodimerization or β-hydride elimination, thus leading to new knowledge in cross-electrophile reactions.

Synthesis and evaluation of novel modified γ-lactam prostanoids as EP4 subtype-selective agonists

To identify chemically and metabolically stable subtype-selective EP4 agonists, design and synthesis of a series of modified γ-lactam prostanoids has been continued. Prostanoids bearing 2-oxo-1,3-oxazolidine, 2-oxo-1,3-thiazolidine and 5-thioxopyrrolidine as a surrogate for the γ-hydroxycyclopentanone without a troublesome 11-hydroxy group were identified as highly subtype-selective EP4 agonists. Among the tested, several representative compounds demonstrated in vivo efficacy after oral dosing in rats. Their pharmacokinetic and structure-activity relationship studies are presented.

Alpha-helical mimetics

Benzoyl urea derivatives that are alpha helical peptides mimetics that mimic BH3-only proteins, compositions containing them, their conjugation to cell-targeting-moieties, and their use in the regulation of cell death are disclosed. The benzoyl urea derivatives are capable of binding to and neutralizing pro-survival Bcl-2 proteins. Use of benzoyl urea derivatives in the treatment and/or prophylaxis of diseases or conditions associated with deregulation of cell death are also described.

New N-arachidonoylserotonin analogues with potential "dual" mechanism of action against pain

N-Arachidonoylserotonin (AA-5-HT, 1a) is an inhibitor of fatty acid amide hydrolase (FAAH) that acts also as an antagonist of transient receptor potential vanilloid-type 1 (TRPV1) channels and is analgesic in rodents. We modified the chemical structure of 1a with the aim of developing "hybrid" FAAH/TRPV1 blockers more potent than the parent compound or obtaining analogues with single activity at either of the two targets to study the mechanism of the analgesic action of 1a. Thirty-eight AA-5-HT analogues, containing a serotonin "head" bound to a variety of lipophilic moieties via amide, urea, or carbamate functionalities, were synthesized. Unlike 1a, most of the new compounds possessed activity at only one of the two considered targets. The amides 1b and 1c of α- and γ-linolenic acid, however, showed "hybrid" activity similar to 1a. The carbamate 3f (OMDM106), although unable to antagonize TRPV1 receptors, was the most potent FAAH inhibitor in this study (IC50 = 0.5 μM). Compounds 3f and 1m (OMDM129), which exhibited activity at only FAAH or TRPV1, respectively, were 10-fold less potent than 1a at preventing formalin-induced hyperalgesia in mice.

INHIBITORS OF FATTY ACID SYNTHASE (FAS)

The instant invention provides for compounds which comprise substituted 3-aryl-4-hydroxyquinolin-2(1H)-ones that inhibit FAS activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting FAS activity

Compositions and methods of treating cell proliferation disorders

The invention relates to compounds and methods for treating cell proliferation disorders.